The clinical success and approval of selective RET inhibitors for MTC and PTC, with fewer off-target adverse events and more effective and sustained anti-tumour activity compared with MKIs, have facilitated thyroid cancer entering precision oncology for the RET-dependent cancers, RET-mutant MTC and RET fusion-positive PTC. The gene discussed is RET; the disease is thyroid cancer.